Advertisement
3PBIOVIAN to collaborate with Eleva

The two companies have announced a strategic alliance to collaborate on the manufacturing of current pipeline programs and potential future programs based on Eleva’s technology platform.
Under the terms of the agreement, Eleva secures production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programs into mid- to late-stage clinical development. This covers Factor H (CPV-104), a novel complement modulator currently being developed in C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD).

Navigating the Financial Landscape: Merger
Combining the strengths of two companies is a way to position against competitors and also become more resilient to a fluctuating financial market.
Additionally, 3PBIOVIAN acquires a non-exclusive license to Eleva’s expression system. As a result of the alliance, Eleva essentially triples its offering of GMP production capacity for programs based on its technology platform.
“We are delighted that Eleva has selected us as a partner for the manufacturing of clinical material for their current pipeline programs, including their novel complement regulator Factor H (CPV-104), which could provide patients with a much-needed new therapeutic option. Access to Eleva’s expression system also supports our commitment to meet the evolving needs of biopharmaceutical developers by continuously expanding our capabilities. Moss-based expression adds a valuable new dimension to our established high-quality offerings in biologics manufacturing,” says Dámaso Molero Sánchez, Group CEO at 3PBIOVIAN.
Published: February 4, 2025
Advertisement